Omnicell (OMCL) Stock Rating Lowered by BidaskClub

Omnicell (NASDAQ:OMCL) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday.

A number of other brokerages have also recently issued reports on OMCL. Cantor Fitzgerald upped their price objective on shares of Omnicell to $58.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Oppenheimer reiterated a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a report on Thursday, October 19th. Craig Hallum reiterated a “buy” rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Finally, Zacks Investment Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. Omnicell has an average rating of “Hold” and a consensus price target of $55.14.

Omnicell (NASDAQ:OMCL) traded up $1.15 during trading on Friday, hitting $51.70. 139,984 shares of the stock traded hands, compared to its average volume of 155,288. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53. Omnicell has a fifty-two week low of $32.70 and a fifty-two week high of $55.40.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting the consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same period in the previous year, the company posted $0.40 EPS. Omnicell’s revenue was up 5.7% on a year-over-year basis. equities analysts expect that Omnicell will post 0.12 earnings per share for the current fiscal year.

In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jorge R. Taborga sold 6,295 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $48.69, for a total transaction of $306,503.55. Following the transaction, the vice president now directly owns 50,013 shares of the company’s stock, valued at approximately $2,435,132.97. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,558 shares of company stock valued at $1,330,230. Company insiders own 3.77% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its position in shares of Omnicell by 9.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 159,341 shares of the company’s stock valued at $6,868,000 after buying an additional 13,215 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Omnicell by 3.5% during the second quarter. Alliancebernstein L.P. now owns 56,746 shares of the company’s stock valued at $2,446,000 after buying an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC raised its position in shares of Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after buying an additional 1,830 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Omnicell by 0.9% during the second quarter. TIAA CREF Investment Management LLC now owns 145,912 shares of the company’s stock valued at $6,289,000 after buying an additional 1,272 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of Omnicell by 0.4% during the second quarter. Ameriprise Financial Inc. now owns 353,917 shares of the company’s stock valued at $15,253,000 after buying an additional 1,386 shares during the last quarter. 99.61% of the stock is owned by hedge funds and other institutional investors.

WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/21/omnicell-omcl-stock-rating-lowered-by-bidaskclub.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply